First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor

Shimizu, H.; A. Tortorici, Michael; Ohta, Yoshiyasu; Ogawa, Kei; Mohammed Ashfaq Rahman, Sheikh; Fujii, Aya; Hiraga, Yuki; Kawai, Mizue; Sugimoto‐Kawabata, Kanami; van Iersel, Mattheus; Jaap van Lier, Jan; Djedjos, Stephen; Taylor Slingsby, Brian; M. Rodman, David

doi:10.1111/cts.70000

Public

First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor

Published in Clinical and Translational Science • Aug 1, 2024

Authors:

H. Shimizu

Michael A. Tortorici

Yoshiyasu Ohta

Abstract

Abstract Dysregulation of the mineralocorticoid hormone aldosterone is an increasingly prevalent cause of hypertension. Aldosterone synthase (CYP11B2) shares 93% homology to 11β‐hydroxylase (CYP11B1), which produces cortisol. Lorundrostat, a highly selective inhibitor of CYP11B2, is a potential safe...

Subject

Aldosterone

Aldosterone synthase

Endocrinology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!